

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF  
SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934  
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Laivins Peter N</u>  (Last) (First) (Middle) <u>C/O MERRIMACK</u> <u>PHARMACEUTICALS, INC.</u> <u>ONE KENDALL SQUARE, SUITE B7201</u>  (Street) <u>CAMBRIDGE MA</u> <u>02139</u>  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>05/14/2014</u>	3. Issuer Name and Ticker or Trading Symbol <u>MERRIMACK PHARMACEUTICALS INC [ MACK ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below)  <u>SVP of Development</u>	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line)  <input checked="" type="checkbox"/> Form filed by One Reporting Person  Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	2,000	D	

Table II - Derivative Securities Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (right to buy)	(1)	11/01/2021	Common Stock	40,000	6.78	D	
Stock Option (right to buy)	(2)	06/12/2022	Common Stock	10,000	6.8	D	
Stock Option (right to buy)	(3)	08/22/2022	Common Stock	22,300	7.53	D	
Stock Option (right to buy)	(4)	03/11/2023	Common Stock	35,000	6.35	D	
Stock Option (right to buy)	(5)	02/10/2024	Common Stock	100,000	5.02	D	

Explanation of Responses:

- 1. This option vested as to 1/6th of the shares on 4/17/12 and vests in equal quarterly installments thereafter until 10/17/14.
- 2. This option vested as to 1/12th of the shares on 9/13/12 and vests in equal quarterly installments thereafter until 6/13/15.
- 3. This option vested as to 1/12th of the shares on 11/23/12 and vests in equal quarterly installments thereafter until 8/23/15.
- 4. This option vested as to 1/12th of the shares on 6/12/13 and vests in equal quarterly installments thereafter until 3/12/16.
- 5. This option vested as to 1/12th of the shares on 5/11/14 and vests in equal quarterly installments thereafter until 2/11/17.

/s/ Jeffrey A. Munsie, attorney- 05/21/2014  
in-fact

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.